Head & Neck Cancers | Specialty

Dr. Randolph on Evolving Role of Surgery for Patients With Thyroid Cancer

September 6th 2016

Gregory W. Randolph, MD, director, General and Thyroid Surgical Services, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, discusses how the role of surgery has evolved for patients with thyroid cancer.

Dr. Joshua M. Bauml on the Impact of Pembrolizumab in Head and Neck Cancer

September 2nd 2016

Expert Says Nivolumab Poised to Change Standard of Care in SCCHN

August 23rd 2016

Robert L. Ferris, MD, PhD, discusses the findings of the CheckMate-141 study, potential biomarkers for nivolumab (Opdivo), and questions that remain regarding the use of the immunotherapy in squamous cell carcinoma of the head and neck.

Pembrolizumab to Have Critical Role in Head and Neck Cancer Treatment

August 21st 2016

Joshua M. Bauml, MD, discusses the impact of pembrolizumab's (Keytruda's) success in recurrent or metastatic head and neck squamous cell carcinoma, the results of the KEYNOTE-055 study, and what he sees on the horizon for the PD-1 inhibitor in this field.

Patient Resistance to Swallowing Exercises After Multimodality Therapy

August 17th 2016

Giselle Carnaby, PhD, professor, ASHA fellow, Communication Sciences and Disorders, University of Central Florida, discusses rehabilitation of swallowing after multimodality therapy in patients with head and neck cancer, and why they may be resistant to it.

Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers

August 16th 2016

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.

Dr. Nussenbaum on Organ Preservation for Patients With Larynx Cancer

August 10th 2016

Brian Nussenbaum, MD, Christy J. and Richard S. Hawes III Professor, Otolaryngology-Head and Neck Surgery, director, Head and Neck Surgical Oncology, vice chair of Clinical Affairs, patient safety officer, Washington University School of Medicine in St. Louis, discusses which patients with larynx cancer are eligible for organ preservation surgery.

FDA Approves Pembrolizumab for Head and Neck Cancer

August 6th 2016

The FDA has granted an accelerated approval to pembrolizumab as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma following progression on a platinum-based chemotherapy.

Dr. Ferris on FDA Approval of Pembrolizumab in Head and Neck Cancer

August 6th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.

Dr. Ranee Mehra on the Importance of Symptom Management in Head and Neck Cancer

August 5th 2016

Dr. Rodriguez on Systemic Therapy in Salivary Gland Cancer

August 4th 2016

Cristina P. Rodriguez, MD, hematology oncologist, University of Washington School of Medicine in Seattle, discusses the emerging role of systemic therapy for patients with salivary gland cancer.

Late-Stage Afatinib Trials Halted in Head and Neck Cancer

July 26th 2016

Two phase III trials examining afatinib (Gilotrif) in head and neck cancer have been stopped after an independent panel determined the pan-HER inhibitor was unlikely to demonstrate an efficacy benefit over placebo.

Vemurafenib Effective for BRAF-Mutant Thyroid Cancer

July 26th 2016

Treatment with vemurafenib (Zelboraf) demonstrated an objective response rate of up to 38.5% for patients with radioactive iodine-refractory BRAF V600E-mutant papillary thyroid cancer who were multikinase inhibitor-naive.

Personalized Strategies Vital in Thyroid Cancer Care

July 23rd 2016

After a decade of advances in the treatment of differentiated thyroid cancer, researchers are looking for ways to improve outcomes through a more personalized approach that includes risk-based strategies and appropriate use of molecular testing.

FDA Grants Nivolumab Priority Review for Head and Neck Cancer

July 18th 2016

The FDA has granted a priority review designation to nivolumab as a treatment for patients with previously treated metastatic or recurrent squamous cell carcinoma of the head and neck.

Lenvatinib PFS Benefit Sustained in Thyroid Cancer

July 15th 2016

The progression-free survival benefit with lenvatinib over placebo in patients with radioactive iodine–refractory differentiated thyroid cancer was sustained in an updated analysis of the phase III SELECT trial.

Dr. Haraf on Induction Chemotherapy With Radiation For Advanced Head and Neck Cancer

July 14th 2016

Individualizing Care for Elderly Patients With Localized Head and Neck Cancer

July 13th 2016

Although paradigms for treating older patients with head and neck cancer are not well defined, advancements in targeted and immunotherapies and less toxic radiation regimens suggest that physicians can aim for a more individualized approach to treating this patient population.

Expert Provides Insight on Biomarker Research in Thyroid Cancer

July 13th 2016

Marcia S. Brose, MD, PhD, sheds light on the biomarker assessment of the DECISION trial and the overall developments with biomarker research in the field of differentiated thyroid cancer.

Pembrolizumab Shows Potential in Advanced Thyroid Cancer

July 12th 2016

Pembrolizumab (Keytruda) demonstrated promising antitumor activity with durable responses in patients with advanced thyroid cancer.